Clinical commissioning policy: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)

Document first published:
Page updated:
Topic:
Publication type:

Trametinib is recommended to be available off-label as a routine commissioning treatment option for adults with recurrent or progressive low grade serous ovarian cancer within the criteria set out in this document.